Virtual—The FDA Office of Women’s Health is hosting a public, virtual meeting to discuss potential sex and gender differences in use and responses to cannabidiol (CBD) and other cannabinoids on Thursday, November 19, 9:00 AM EST – 4:00 PM EST, according to a press release.
Presentations will address patient and healthcare provider perspectives on CBD and other cannabinoid use, sex differences in the effects of cannabinoids, use of cannabinoids in pregnancy, and government agency perspectives on CBD research and evaluation, the press release says.
Related: NH Proposes Regulations for CBD Products
Broad Support for Hemp and Hemp-Derived CBD In Dietary Supplements Is an Industry No Brainer
FDA Rejects Oleandrin As a Supplement
Conditions such as chronic pain, anxiety, depression, and sleep disturbances—all conditions for which CBD is often marketed—are more prevalent in women than men, the press release explains. Therefore, it is particularly important to take any possible sex and gender differences into account, with regards to the safety of CBD and other cannabinoids.
Speaker bios and program forthcoming.